BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xenical (orlistat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Xenical (orlistat)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05816343-124@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Xenical (orlistat): Phase 2 readout est. (NCT05816343)
DESCRIPTION:Xenical (orlistat)\, phase 2.\nStudy: Long Term Efficacy and Sa
 fety of Orlistat for Type 1 Hyperlipoproteinemia\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 orlistat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05816343
URL:https://assetmemo.bio/drug/orlistat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301437-124@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Xenical (orlistat): Phase 4 readout est. (NCT07301437)
DESCRIPTION:Xenical (orlistat)\, phase 4\, Obesity.\nStudy: RWS of of Lirag
 lutide Alone and in Combination With Orlistat for Weight Loss in Overweigh
 t/Obese Patients.\nEstimated primary completion: 31 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/orlistat#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07301437
URL:https://assetmemo.bio/drug/orlistat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714070-124@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Xenical (orlistat): Phase 2 readout est. (NCT07714070)
DESCRIPTION:Xenical (orlistat)\, phase 2.\nStudy: Orlistat Plus Progestin f
 or Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplas
 ia\nEstimated primary completion: September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/orlistat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07714070
URL:https://assetmemo.bio/drug/orlistat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326839-124@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Xenical (orlistat): Phase na readout est. (NCT07326839)
DESCRIPTION:Xenical (orlistat)\, phase na\, Obesity.\nStudy: Orlistat and W
 eight Management for Uric Acid Control in Obese Gout: A RCT\nEstimated pri
 mary completion: 9 November 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/orlistat#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07326839
URL:https://assetmemo.bio/drug/orlistat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
